Immunic Therapeutics

Immunic Therapeutics

Edit info

  • Founded: 2016
  • Location: Grafelfing, Germany
  • Employee range: 50 - 200
  • Clinical stage: Clin3
  • Therapy area: Relapsing MS
  • Drug types: NEU, GI, IMM
  • Lead product: IMU-838
  • Funding: 100-500M


imux.com

linkedin.com

job board


Business:

Small Molecules

Drug notes:

Also Clin2 progressive MS, Clin2 ulcerative colitis; IMU-856 Clin1 celiac disease; IMU-381 Clin0 GI diseases

About:

Immunic Therapeutics is developing orally administered, small molecule programs for chronic inflammatory and autoimmune diseases. The company's unique science is based on its proprietary platform for the discovery and development of small molecule immunomodulators that target the aryl hydrocarbon receptor (AhR). The AhR is a nuclear receptor that plays a key role in regulating the immune system. Immunic Therapeutics' small molecule AhR modulators are designed to selectively activate the AhR in a way that promotes anti-inflammatory and immunomodulatory effects. This makes them promising candidates for the treatment of a wide range of chronic inflammatory and autoimmune diseases.

Post a job


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com